Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2772-2780

  Meirovitz, Amichay ^a   Hermano, Esther ^a   Lerner, Immanuel ^a   Zcharia, Eyal ^a   Pisano, Claudio ^a   Peretz, Tamar ^a   Elkin, Michael ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEPARAN SULFATE; HEPARANASE; HEPARANASE INHIBITOR; SST 0001; TRANSCRIPTION FACTOR EGR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INVASION; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; EARLY GROWTH RESPONSE PROTEIN 1; ENZYME INHIBITORS; GLUCURONIDASE; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS;

EID: 79953293124     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3402     Document Type: Article

References (59)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708.
2. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States:changes below the surface. Aliment Pharmacol Ther 2006;24:87-94. (Pubitemid 43894008)
3. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008;196:430-41.
4. Muller MW, Friess H, Koninger J, Martin D, Wente MN, Hinz U, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 2008;195:221-8.
5. Network N. C. C. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. v.1.2008 , 2008.
6. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005;62:1345-50. (Pubitemid 40982053)
7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. and the European Study Group for Pancreatic, C. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
8. Ohuchida K, Mizumoto K, Murakami M, Qian L.-W, Sato N, Nagai E, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004;64:3215-22. (Pubitemid 38581425)
9. Qian L.-W, Mizumoto K, Urashima T, Nagai E, Maehara N, Sato N, et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 2002;8:1223-7. (Pubitemid 35177378)
10. Camphausen K, Moses MA, Beecken W.-D, Khan M K, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
11. Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005;4:1717-28. (Pubitemid 41685306)
12. Madani I, De Neve W, Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis?Bull Cancer 2008;95:292-300.
13. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006;66:8511-19.
14. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-50. (Pubitemid 32685864)
15. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-39. (Pubitemid 44397619)
16. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-108.
17. Vlodavsky I, Goldshmidt O, Zcharia E, Metzger S, Chajek-Shaul T, Atzmon R, et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie 2001;83:831-9. (Pubitemid 32821249)
18. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77. (Pubitemid 29449208)
19. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52. (Pubitemid 28411140)
20. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8. (Pubitemid 37328933)
21. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996;15:177-86. (Pubitemid 26236115)
22. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. Faseb J 2001;15:1661-3.
23. Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 2008;6:1-9. (Pubitemid 351378161)
24. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998;4:691-7. (Pubitemid 28274669)
25. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006;118:1609-17. (Pubitemid 43376422)
26. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008;14:668-76. (Pubitemid 351231146)
27. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood 2007;109:4914-23.
28. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:1303-9. (Pubitemid 40170907)
29. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110:2041-8. (Pubitemid 47443921)
30. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802. (Pubitemid 29318614)
31. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, Marchetti D. Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia 2005;7:253-62. (Pubitemid 40411637)
32. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004;96:1219-30. (Pubitemid 39232713)
33. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-59. (Pubitemid 32691870)
34. Quiros RM, Rao G, Plate J, Harris JE, Brunn GJ, Platt JL,et al. Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 2006;106:532-40.
35. Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002;86:1270-5.
36. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, et al. High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 2008;12:1674-81; discussion 1681-72.
37. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005;280:12103-13.
38. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, Joyce JA, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008;283:18167-76.
39. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003;63:8749-56. (Pubitemid 38064053)
40. Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S, Kleinman HK, et al. Heparanase regulates murine hair growth. Am J Pathol 2005;166:999-1008. (Pubitemid 40524425)
41. de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 2005;280:35136-47. (Pubitemid 41532700)
42. de Mestre AM, Khachigian LM, Santiago FS, Staykova MA, Hulett MD. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 2003;278:50377-85. (Pubitemid 37548881)
43. Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP Jr, Sells SF, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 1996;271:29231-7. (Pubitemid 26382635)
44. Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D, Weichselbaum RR, et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A 1992;89:10149-53.
45. Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, et al. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 2009;28:1121-31.
46. Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003;63:8821-6. (Pubitemid 38064061)
47. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
48. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, Vlodavsky I, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. Faseb J 2007;21:3562-72. (Pubitemid 350075146)
49. Kaplan HS, Murphy ED. The effect of local roentgen irradiation on the biological behavior of a transplantable mouse carcinoma; increased frequency of pulmonary metastasis. J Natl Cancer Inst 1949;9:407-13.
50. Suit HD, Sedlacek RS, Gillette EL. Examination for a correlation between probabilities of development of distant metastasis and of local recurrence. Radiology 1970;95:189-94.
51. von Essen CF. Radiation enhancement of metastasis: a review. Clin Exp Metastasis 1991;9:77-104.
52. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 2008;49:207-10.
53. de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 2007;82:1289-1300. (Pubitemid 350133527)
54. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem 2006;281:15129-37. (Pubitemid 43855102)
55. Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 2007;56:1275-82. (Pubitemid 47300430)
56. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75. (Pubitemid 350007692)
57. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V.Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 1983;43:2704-11. (Pubitemid 13100536)
58. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999;83:424-31. (Pubitemid 29455768)
59. Cohen I, Maly B, Simon I, Meirovitz A, Pikarsky E, Zcharia E, et al. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:4069-77. (Pubitemid 47105967)